---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-083011"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T22:11:30.732851+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protara Q3 net loss $9.9M; cash $74M; TARA-002 trials advance with results expected 1H24

## Summary
- Q3 2023 net loss of $9.9M ($0.87/shr) vs $7.7M ($0.68/shr) in Q3 2022.
- Cash, cash equivalents & investments of $74.0M as of Sept 30, expected to fund ops into Q2 2025.
- R&D expenses rose to $6.2M from $3.5M, driven by TARA-002 clinical trial activities.
- First patient dosed in Phase 2 ADVANCED-2 (NMIBC) and Phase 2 STARBORN-1 (lymphatic malformations) trials.
- Preliminary results from ADVANCED-1EXP expansion trial in NMIBC on track for 1H24.

## SEC filing metadata
- accession: 0001213900-23-083011
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/ea187484-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-083011
- JSON: https://secwatch.observer/filing/0001213900-23-083011.json
- Plain text: https://secwatch.observer/filing/0001213900-23-083011.txt

## Key facts
- Earnings Releases
  Protara Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income net loss of $9.9 million, EPS $0.87 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: net loss of $9.9 million
  - EPS: $0.87 per share
  - Result: reported results
  source text: For the third quarter of 2023, Protara reported a net loss of $9.9 million, or $0.87 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1359931/000121390023083011/0001213900-23-083011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.